Nargesi Arash Aghajani, Lerman Lilach O, Eirin Alfonso
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States.
Curr Gene Ther. 2017;17(1):29-42. doi: 10.2174/1566523217666170412110724.
Transplantation of autologous mesenchymal stem cells (MSCs) has been shown to attenuate renal injury and dysfunction in several animal models, and its efficacy is currently being tested in clinical trials for patients with renal disease. Accumulating evidence indicates that MSCs release extracellular vesicles (EVs) that deliver genes, microRNAs and proteins to recipient cells, acting as mediators of MSC paracrine actions. In this context, it is critical to characterize the MSC-derived EV cargo to elucidate their potential contribution to renal repair. In recent years, researchers have performed high-throughput sequencing and proteomic analysis to detect and identify genes, microRNAs, and proteins enriched in MSC-derived EVs.
The present review summarizes the current knowledge of the MSC-derived EV secretome to shed light into the mechanisms mediating MSC renal repair, and discusses preclinical and clinical studies testing the efficacy of MSC-derived EVs for treating renal disease.
在多种动物模型中，自体间充质干细胞（MSC）移植已显示出可减轻肾损伤和功能障碍，目前其疗效正在针对肾病患者的临床试验中进行测试。越来越多的证据表明，MSC释放细胞外囊泡（EV），这些囊泡将基因、微小RNA和蛋白质传递给受体细胞，充当MSC旁分泌作用的介质。在此背景下，表征MSC来源的EV货物以阐明它们对肾脏修复的潜在贡献至关重要。近年来，研究人员进行了高通量测序和蛋白质组学分析，以检测和鉴定富含MSC来源的EV中的基因、微小RNA和蛋白质。
本综述总结了目前关于MSC来源的EV分泌组的知识，以阐明介导MSC肾脏修复的机制，并讨论了测试MSC来源的EV治疗肾病疗效的临床前和临床研究。
